EX-1.2 3 d88473dex12.htm EX-1.2 EX-1.2

Exhibit 1.2

PRICING AGREEMENT

February 24, 2026

Barclays Capital Inc.

BofA Securities, Inc.

Citigroup Global Markets Inc.

Goldman Sachs & Co. LLC

Morgan Stanley & Co. LLC

Wells Fargo Securities, LLC

As Representatives of the several Underwriters named in Schedule I hereto

c/o Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

c/o BofA Securities, Inc.

One Bryant Park

New York, New York 10036

c/o Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

c/o Goldman Sachs & Co. LLC

200 West Street

New York, New York 10282

c/o Morgan Stanley & Co. LLC

1585 Broadway, 29th Floor

New York, New York 10036

c/o Wells Fargo Securities, LLC

550 South Tryon Street, 5th Floor

Charlotte, North Carolina 28202

Ladies and Gentlemen:

MetLife, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein (this “Agreement”) and in the Underwriting Agreement, dated February 24, 2026 (the “Underwriting Agreement”), to issue and sell to the Underwriters named in Schedule I hereto (the “Underwriters”) the principal amounts of its Securities specified in Schedule I hereto.


Each of the provisions of the Underwriting Agreement is incorporated herein by reference in its entirety, and shall be deemed to be a part of this Agreement to the same extent as if such provisions had been set forth in full herein; and each of the representations and warranties set forth therein shall be deemed to have been made at and as of the date of this Agreement, the Applicable Time, and the Closing Date. Each reference to the Representatives herein and in the provisions of the Underwriting Agreement so incorporated by reference shall be deemed to refer to you. A reference to the Indenture shall be deemed to refer to the Indenture, dated as of June 21, 2005, between the Company and The Bank of New York Mellon Trust Company, N.A. (as successor in interest to J.P. Morgan Trust Company, National Association) (the “Subordinated Trustee”), as supplemented by the Fourteenth Supplemental Indenture, to be dated as of February 26, 2026, between the Company and the Subordinated Trustee. Unless otherwise defined herein, terms defined in the Underwriting Agreement are used herein as therein defined. The Representatives designated to act on behalf of the Underwriters of the Securities pursuant to the Underwriting Agreement are designated as the “Joint Book-Running Managers” at the end of Schedule II hereto.

Subject to the terms and conditions set forth herein and in the Underwriting Agreement incorporated herein by reference, at the time and at the purchase price to the Underwriters set forth in Schedule III hereto, the Company agrees to issue, sell and deliver to each of the Underwriters, and each of the Underwriters agrees, severally and not jointly, to purchase from the Company, at the time and at the purchase price to the Underwriters set forth in Schedule III hereto, the principal amounts of Securities set forth opposite the name of such Underwriter in Schedule I hereto. The date of the issuance, sale and delivery of the Securities is the “Settlement Date” set forth on Schedule II hereto and such date shall be considered a Closing Date under the Underwriting Agreement.

If the foregoing is in accordance with your understanding, please sign and return to us counterparts hereof, and upon acceptance hereof by you, on behalf of each of the Underwriters, this letter and such acceptance hereof, including the provisions of the Underwriting Agreement incorporated herein by reference, shall constitute a binding agreement between each of the Underwriters and the Company. It is understood that your acceptance of this letter on behalf of each of the Underwriters is or will be pursuant to the authority set forth in a form of Agreement among Underwriters, the form of which shall be submitted to the Company for examination upon request, but without warranty on the part of the Representatives as to the authority of the signers thereof.

[Signature pages follow]

 

2


Very truly yours,
METLIFE, INC.
By:  

/s/ John A. Hall

Name:   John A. Hall
Title:   Executive Vice President and
  Treasurer

 

[Signature Page to Pricing Agreement]


Accepted as of the date hereof on behalf of each of the Underwriters:

 

BARCLAYS CAPITAL INC.
By:  

/s/ Tom McIntosh

Name: Tom McIntosh
Title: Managing Director

 

[Signature Page to Pricing Agreement]


BOFA SECURITIES, INC.
By:  

/s/ Randolph B. Randolph

Name: Randolph B. Randolph
Title: Managing Director

 

[Signature Page to Pricing Agreement]


CITIGROUP GLOBAL MARKETS INC.
By:  

/s/ Adam D. Bordner

Name: Adam D. Bordner
Title: Managing Director

 

[Signature Page to Pricing Agreement]


GOLDMAN SACHS & CO. LLC
By:  

/s/ John Sales

Name: John Sales
Title: Managing Director

 

[Signature Page to Pricing Agreement]


MORGAN STANLEY & CO. LLC
By:  

/s/ Courtney McCauley

Name: Courtney McCauley
Title: Vice President

 

[Signature Page to Pricing Agreement]


WELLS FARGO SECURITIES, LLC
By:  

/s/ Carolyn Hurley

Name: Carolyn Hurley
Title: Managing Director

 

[Signature Page to Pricing Agreement]


SCHEDULE I

TO PRICING AGREEMENT

 

Underwriters

   Principal Amount of $1,000,000,000 5.850% Fixed-to-Fixed Reset  Rate
Subordinated Debentures due 2056 to be Purchased

Barclays Capital, Inc.

   $140,000,000

BofA Securities, Inc.

   $140,000,000

Citigroup Global Markets Inc.

   $140,000,000

Goldman Sachs & Co. LLC

   $140,000,000

Morgan Stanley & Co. LLC

   $140,000,000

Wells Fargo Securities, LLC

   $140,000,000

BNP Paribas Securities Corp.

   $14,000,000

Deutsche Bank Securities Inc.

   $14,000,000

J.P. Morgan Securities LLC

   $14,000,000

Mizuho Securities USA LLC

   $14,000,000

SG Americas Securities, LLC

   $14,000,000

SMBC Nikko Securities America, Inc.

   $14,000,000

TD Securities (USA) LLC

   $14,000,000

BMO Capital Markets Corp.

   $8,000,000

HSBC Securities (USA) Inc.

   $8,000,000

Santander US Capital Markets LLC

   $8,000,000

Scotia Capital (USA) Inc.

   $8,000,000

Truist Securities, Inc.

   $8,000,000

U.S. Bancorp Investments, Inc.

   $8,000,000

Drexel Hamilton, LLC

   $4,700,000

AmeriVet Securities, Inc.

   $4,650,000

Independence Point Securities LLC

   $4,650,000
  

 

Total

   $1,000,000,000

 

Schedule I - 1


SCHEDULE II

TO PRICING AGREEMENT

Filed pursuant to Rule 433

February 24, 2026

Relating to

Preliminary Prospectus Supplement dated February 24, 2026 to

Prospectus dated May 16, 2025

Registration Statement No. 333-287370

 

LOGO

MetLife, Inc.

$1,000,000,000 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056

Final Term Sheet

February 24, 2026

The information in this final term sheet relates to the offering of the securities specified herein and should be read together with the preliminary prospectus supplement dated February 24, 2026 (the “Preliminary Prospectus Supplement”), including the documents incorporated by reference therein, and the accompanying prospectus dated May 16, 2025, filed pursuant to Rule 424(b) under the Securities Act of 1933 (Registration Statement File No. 333-287370). This final term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement. Capitalized terms used but not defined herein shall have the respective meanings as set forth in the Preliminary Prospectus Supplement.

 

Issuer:    MetLife, Inc. (“Issuer”)
Securities:    5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056 (“Debentures”)
Ranking:    Subordinated Unsecured (junior to all existing and future Senior Indebtedness; on parity with the Issuer’s 6.350% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2055; senior to all existing and future equity securities and the Junior Subordinated Obligations)
Aggregate Principal Amount:    $1,000,000,000
Price to the Public:    100.000% of principal amount, plus accrued interest, if any, from February 26, 2026
Underwriting Discount:    1.000%
Net Proceeds**:    $990,000,000
Maturity Date:    March 15, 2056
Trade Date:    February 24, 2026


Settlement Date***:    February 26, 2026 (T+2)
Interest Reset Date:    March 15, 2036 (“Initial Interest Reset Date”) and each date falling on the five-year anniversary of the preceding Interest Reset Date
Interest Reset Period:    The period from, and including, the Initial Interest Reset Date to, but excluding, the next following Interest Reset Date and thereafter each period from, and including, each Interest Reset Date to, but excluding, the next following Interest Reset Date
Interest Payment Dates:    Subject to the Option to Defer Interest Payments, semi-annually in arrears on March 15 and September 15 of each year, beginning on September 15, 2026, and ending on the Maturity Date
Interest Rate:    Subject to the Option to Defer Interest Payments, (i) 5.850%, accruing from, and including, February 26, 2026, to, but excluding, the Initial Interest Reset Date or any earlier redemption date; (ii) from, and including, the Initial Interest Reset Date, during each Interest Reset Period, at an annual rate equal to the Five-Year Treasury Rate as of the most recent Reset Interest Determination Date plus 1.817%
Option to Defer Interest Payments:    So long as no Event of Default with respect to the Debentures has occurred and is continuing, the Issuer has the right to defer the payment of interest on the Debentures for one or more consecutive Interest Periods that do not exceed five years for any single Optional Deferral Period. The Issuer may not defer interest beyond the Maturity Date, any earlier accelerated Maturity Date arising from an Event of Default or any other earlier redemption of the Debentures. During an Optional Deferral Period, interest will continue to accrue on the Debentures at the then-applicable rate described above and deferred interest on the Debentures will bear additional interest at the then-applicable interest rate, compounded on each Interest Payment Date, subject to applicable law. If the Issuer has paid all deferred interest (including compounded interest thereon) on the Debentures, the Issuer can again defer interest payments on the Debentures as described above.
Day Count Convention:    30/360
Optional Redemption:    Redeemable in whole, at any time, or in part, from time to time, (i) on any Interest Payment Date on or after the Initial Interest Reset Date, at a redemption price equal to 100% of the principal amount of Debentures being redeemed, and (ii) prior to the Initial Interest Reset Date, at a redemption price equal to the greater of

 

2


  

(1)   100% of the principal amount of the Debentures to be redeemed, and

 

(2)   (a) the sum of the present values of the remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the Debentures matured on the Initial Interest Reset Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate plus 30 basis points less (b) interest accrued to, but excluding, the redemption date;

 

plus, in each case, accrued and unpaid interest thereon to, but excluding, the redemption date; provided that if the Debentures are not redeemed in whole, at least $25 million aggregate principal amount of the Debentures, excluding any Debentures held by MetLife, Inc. or any of its affiliates, must remain outstanding after giving effect to such redemption and all accrued and unpaid interest, including deferred interest (including compounded interest thereon), must be paid in full on all outstanding Debentures for all Interest Periods ending on or before the redemption date.

Redemption after the Occurrence of a Tax Event, Rating Agency Event or Regulatory Capital Event:    Redeemable in whole, but not in part, at any time, within 90 days after the occurrence of a “Tax Event,” a “Rating Agency Event” or a “Regulatory Capital Event” at a redemption price equal to (i) in the case of a Tax Event or a Regulatory Capital Event, 100% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date or (ii) in the case of a Rating Agency Event, 102% of their principal amount plus accrued and unpaid interest to, but excluding, the redemption date.
Denominations:    $2,000 and integral multiples of $1,000 in excess thereof
CUSIP:    59156R CR7
ISIN:    US59156RCR75
Joint Book-Running Managers:   

Barclays Capital Inc.

BofA Securities, Inc.

Citigroup Global Markets Inc.

Goldman Sachs & Co. LLC

Morgan Stanley & Co. LLC

Wells Fargo Securities, LLC

 

3


Senior Co-Managers:   

BNP Paribas Securities Corp.

Deutsche Bank Securities Inc.

J.P. Morgan Securities LLC

Mizuho Securities USA LLC

SG Americas Securities, LLC

SMBC Nikko Securities America, Inc.

TD Securities (USA) LLC

Co-Managers:   

BMO Capital Markets Corp.

HSBC Securities (USA) Inc.

Santander US Capital Markets LLC

Scotia Capital (USA) Inc.

Truist Securities, Inc.

U.S. Bancorp Investments, Inc.

Junior Co-Managers:   

AmeriVet Securities, Inc.

Drexel Hamilton, LLC

Independence Point Securities LLC

**Net Proceeds are net of Underwriting Discount and prior to expenses.

***It is expected that delivery of the Debentures will be made on or about February 26, 2026, which will be the second business day (T+2) following the date hereof. Under Rule 15c6-1 under the Securities Exchange Act of 1934, trades in the secondary market generally are required to settle in one business day (T+1), unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Debentures more than one business day prior to the scheduled settlement date will be required, by virtue of the fact that the Debentures will initially settle in T+2, to specify an alternative settlement arrangement at the time of any such trade to prevent a failed settlement. Purchasers of the Debentures who wish to trade the Debentures more than one business day prior to the scheduled settlement date should consult their own advisors.

The Issuer has filed a registration statement (including a prospectus) with the SEC for the offering to which this communication relates. Before you invest, you should read the prospectus in that registration statement and other documents the Issuer has filed with the SEC for more complete information about the Issuer and this offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, the Issuer, any underwriter or any dealer participating in this offering will arrange to send you the prospectus if you request it by calling Barclays Capital Inc. toll-free at 1-888-603-5847, BofA Securities, Inc. toll-free at 1-800-294-1322, Citigroup Global Markets Inc. toll-free at 1-800-831-9146, Goldman Sachs & Co. LLC toll-free at 1-866-471-2526, Morgan Stanley & Co. LLC toll-free at 1-866-718-1649 or Wells Fargo Securities, LLC toll-free at 1-800-645-3751.

 

4


SCHEDULE III

TO PRICING AGREEMENT

Underwriters’ Purchase Price of the $1,000,000,000 5.850% Fixed-to-Fixed Reset Rate Subordinated Debentures due 2056: 99.000% of the principal amount thereof

Closing Date: February 26, 2026

Addresses for Notices, etc. to the Representatives:

c/o Barclays Capital Inc.

745 Seventh Avenue

New York, New York 10019

c/o BofA Securities, Inc.

One Bryant Park

New York, New York 10036

c/o Citigroup Global Markets Inc.

388 Greenwich Street

New York, New York 10013

c/o Goldman Sachs & Co. LLC

200 West Street

New York, New York 10282

c/o Morgan Stanley & Co. LLC

1585 Broadway, 29th Floor

New York, New York 10036

c/o Wells Fargo Securities, LLC

550 South Tryon Street, 5th Floor

Charlotte, North Carolina 28202